[
    [
        {
            "time": "",
            "original_text": "甘李药业：在研产品获得美国FDA孤儿药资格认定",
            "features": {
                "keywords": [
                    "甘李药业",
                    "在研产品",
                    "FDA",
                    "孤儿药",
                    "资格认定"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "甘李药业：在研产品获得美国FDA孤儿药资格认定",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "甘李药业(603087.SH)：在研创新药“GLR2007”获得美国FDA孤儿药资格认定",
            "features": {
                "keywords": [
                    "甘李药业",
                    "GLR2007",
                    "创新药",
                    "FDA",
                    "孤儿药",
                    "资格认定"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "甘李药业(603087.SH)：在研创新药“GLR2007”获得美国FDA孤儿药资格认定",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "高瓴资本概念股普遍强势，国瓷材料、广联达、金域医学、甘李药业领涨",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "概念股",
                    "国瓷材料",
                    "广联达",
                    "金域医学",
                    "甘李药业",
                    "领涨"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "科技",
                    "材料"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "高瓴资本概念股普遍强势，国瓷材料、广联达、金域医学、甘李药业领涨",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]